Mark Moster
Neuro-ophthalmology · Philadelphia, PANPI 1376511980
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,427 of the $53,152 with a category attached, or 64.8%. Sanofi accounts for 64.1% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2021 at $17,602 and has fallen 95.9% since, to $724 in 2025.
Across 219 payments — averaging $242.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$34K
- Amgen$12K
- Bausch & Lomb Americas Inc.$1K
- Glaukos Corporation$1K
- Alcon$758
- Biogen$616
- plus $4K from 22 others
What the payments were for
- Consulting fees$6,43512%
- Speaking & faculty fees$34,42765%
- Travel & lodging$2,3724%
- Food & beverage$9,87319%
- Education$250%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 42 | $34,079 |
| Amgen(2 entities) | 51 | $11,784 |
| Bausch & Lomb Americas Inc. | 10 | $1,084 |
| Glaukos Corporation | 10 | $1,045 |
| Alcon | 5 | $758 |
| Biogen | 12 | $616 |
| Novartis | 28 | $534 |
| Aerie Pharmaceuticals, Inc. | 7 | $499 |
| AbbVie(2 entities) | 7 | $457 |
| Sight Sciences, Inc. | 4 | $368 |
| Genentech USA, Inc. | 11 | $347 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $300 |
| AstraZeneca | 2 | $230 |
| NEW World Medical,inc. | 2 | $197 |
| Mallinckrodt Hospital Products Inc. | 5 | $154 |
| Argenx US, Inc. | 3 | $149 |
| Ivantis, Inc | 1 | $125 |
| W. L. Gore & Associates, Inc. | 2 | $79 |
| Johnson & Johnson | 3 | $69 |
| Merz Pharmaceuticals, LLC | 2 | $65 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Thea Pharma Inc. | 1 | $42 |
| EMD Serono, Inc. | 1 | $35 |
| Merz North America, Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $16 |
| TG Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUBAGIO$33,442
- TEPEZZA$5,933
- VYZULTA$738
- Rocklatan$633
- TECFIDERA$372
- XEN GLAUCOMA TREATMENT SYSTEM$242
- OMNI$217
- Actemra$202
- iStent inject W$180
- MIEBO$159
- XIIDRA$159
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$148
- iStent infinite Trabecular Micro-Bypass System Model iS3$148
- Hydrus Microstent$132
- Rhopressa$127
- Hydrus$125
- SOLIRIS$123
- MAYZENT$117
How this compares
Too few neuro-ophthalmology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide | 42 | $3,557 |
| Prednisone | 34 | $397 |
Paid to pharmacies, not to this prescriber.
Other neuro-ophthalmology in Philadelphia
- Robert SergottPhiladelphia$1.5M
- Madhura TamhankarPhiladelphia$126K
- Adam DebuskPhiladelphia$23K
- Shruthi Harish BindiganavilePhiladelphia$755
- Ramya GnanarajPhiladelphia$459
- Kenneth ShindlerPhiladelphia$47
- Gil BinenbaumPhiladelphia$0
- Peter MortensenPittsburgh$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.